Evidence map›Paper›PMID 39956818›Full record

ArticleScientific reports2025

Identification of IGF2BPs-related mRNA signature for predicting the overall survival of lung adenocarcinoma.

Xiang Xu, Weidi Zhao, Di Peng, Ying Sun, Jicheng Tantai, Guofang Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiang Xu *Department of Thoracic Surgery, Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No. 2 Hospital), Ningbo No. 2 Hospital), No.41 Xibei Road, Ningbo, China.
Weidi Zhao *Department of Thoracic Surgery, Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No. 2 Hospital), Ningbo No. 2 Hospital), No.41 Xibei Road, Ningbo, China.
Di PengDepartment of Data Science, Burning Rock Biotech, Guangzhou, China.
Ying SunDepartment of Data Science, Burning Rock Biotech, Guangzhou, China.
Jicheng TantaiDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, No.241 West Huaihai Road, Xuhui District, Shanghai, China. 46546047@qq.com.
Guofang ZhaoDepartment of Thoracic Surgery, Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No. 2 Hospital), Ningbo No. 2 Hospital), No.41 Xibei Road, Ningbo, China. zhaoguofang@ucas.ac.cn.

Funding

Hwamei Fund 2019HMZDKY04 and 2022HMKY37Natural Science Foundation of Ningbo 2019A610225Ningbo Health Branding Subject Fund PPXK2018-05The Key discipline of Hwamei Hospital, University of Chinese Academy of Science 2020ZDXK03The Medical Health Science and Technology Project of Zhejiang Provincial Health Commission 2021KY1009 and 2022KY1138
6 · The paper itself

Abstract

Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) are m⁶A readers that stabilize target mRNAs by recognizing the GG(m⁶A)C sequence. While previous studies have explored the biological mechanisms of IGF2BPs in lung cancer, their prognostic value remains unclear. This study investigated the expression, molecular mechanisms, and prognostic significance of IGF2BPs in lung adenocarcinoma (LUAD) using TCGA and GEO datasets. IGF2BP1/2/3 were found to be highly expressed in LUAD, with high mRNA stability scores (RS) associated with shorter overall survival (OS) and linked to hypoxia, EMT, IL2-STAT5 signaling, immune suppression, and decreased gefitinib sensitivity. In cell-based experiments, siRNA knockdown of IGF2BPs in LUAD cell lines reduced TGF-β signaling pathway-related genes and inhibited cell proliferation. Our findings suggest that the IGF2BPs gene signature is a prognostic biomarker in LUAD, contributing to tumor progression, immune escape, and poor prognosis by activating specific pathways.

Indexed as

Adenocarcinoma of LungLung NeoplasmsRNA-Binding ProteinsRNA, MessengerBiomarkers, TumorCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansPrognosisRNA StabilitySignal TransductionBiomarkers, TumorIGF2BP1 protein, humanIGF2BP2 protein, humanIGF2BP3 protein, humanRNA-Binding ProteinsRNA, MessengerHypoxiaIGF2BPsIL2-STAT5Lung adenocarcinomaM6APrognosis

Identifiers

PMID39956818
PMCPMC11830784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.